BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC, Ferreira T, Pulit SL, Glastonbury CA, Laber S, Millwood IY, Lin K, Li L, Chen Z, Milani L, Smith GD, Walters RG, Mägi R, Neale BM, Lindgren CM, Holmes MV. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med 2020;12:eaay6570. [PMID: 32581134 DOI: 10.1126/scitranslmed.aay6570] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Wang L, Ni S, Li D, Liu J, Chu HY, Zhang N, Sun M, Li N, Ren Q, Zhuo Z, Zhong C, Xie D, Li Y, Zhang Z, Zhang H, Li M, Zhang Z, Chen L, Pan X, Xia W, Zhang S, Lu A, Zhang B, Zhang G. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-31997-8] [Reference Citation Analysis]
2 Li Y, Gu Z, Wang J, Wang Y, Chen X, Dong B. The Emerging Role of Bone-Derived Hormones in Diabetes Mellitus and Diabetic Kidney Disease. Front Endocrinol 2022;13:938830. [DOI: 10.3389/fendo.2022.938830] [Reference Citation Analysis]
3 Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2022;42:e187-202. [PMID: 35546488 DOI: 10.1161/ATVBAHA.122.317635] [Reference Citation Analysis]
4 Yu S, Li D, Zhang N, Ni S, Sun M, Wang L, Xiao H, Liu D, Liu J, Yu Y, Zhang Z, Yeung STY, Zhang S, Lu A, Zhang Z, Zhang B, Zhang G. Drug discovery of sclerostin inhibitors. Acta Pharm Sin B 2022;12:2150-70. [PMID: 35646527 DOI: 10.1016/j.apsb.2022.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC, Ferreira T, Pulit SL, Glastonbury CA, Laber S, Millwood IY, Lin K, Li L, Chen Z, Milani L, Smith GD, Walters RG, Mägi R, Neale BM, Lindgren CM, Holmes MV. Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". Sci Transl Med 2021;13:eabf4530. [PMID: 34851696 DOI: 10.1126/scitranslmed.abf4530] [Reference Citation Analysis]
6 Hólm H, Sulem P, Tragante V, Thorsteinsdottir U, Gudbjartsson DF, Stefansson K. Comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". Sci Transl Med 2021;13:eabe8497. [PMID: 34851692 DOI: 10.1126/scitranslmed.abe8497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Feehan J, Tripodi N, Fleischmann M, Zanker J, Duque G. A clinician's guide to the management of geriatric musculoskeletal disease: Part 1 - Osteoporosis. International Journal of Osteopathic Medicine 2021. [DOI: 10.1016/j.ijosm.2021.12.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cejka D. Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease. Metabolites 2021;11:770. [PMID: 34822428 DOI: 10.3390/metabo11110770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Takeuchi Y. Romosozumab and cardiovascular safety in Japan. Osteoporos Sarcopenia 2021;7:89-91. [PMID: 34632110 DOI: 10.1016/j.afos.2021.09.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Langdahl BL, Hofbauer LC, Forfar JC. Cardiovascular Safety and Sclerostin Inhibition. J Clin Endocrinol Metab 2021;106:1845-53. [PMID: 33755157 DOI: 10.1210/clinem/dgab193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Skrzypczyk P, Ofiara A, Szyszka M, Stelmaszczyk-Emmel A, Górska E, Pańczyk-Tomaszewska M. Serum Sclerostin Is Associated with Peripheral and Central Systolic Blood Pressure in Pediatric Patients with Primary Hypertension. J Clin Med 2021;10:3574. [PMID: 34441870 DOI: 10.3390/jcm10163574] [Reference Citation Analysis]
12 Shah M, Appuswamy AV, Rao SD, Dhaliwal R. Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic? Curr Opin Endocrinol Diabetes Obes 2021;28:377-82. [PMID: 34010225 DOI: 10.1097/MED.0000000000000645] [Reference Citation Analysis]
13 Li SS, He SH, Xie PY, Li W, Zhang XX, Li TF, Li DF. Recent Progresses in the Treatment of Osteoporosis. Front Pharmacol 2021;12:717065. [PMID: 34366868 DOI: 10.3389/fphar.2021.717065] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Rodríguez AJ, Abrahamsen B. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. JBMR Plus 2021;5:e10522. [PMID: 34258509 DOI: 10.1002/jbm4.10522] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Hassan N, Gregson CL, Tobias JH. Anabolic treatments for osteoporosis in postmenopausal women. Fac Rev 2021;10:44. [PMID: 34131654 DOI: 10.12703/r/10-44] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med 2021;10:1660. [PMID: 33924496 DOI: 10.3390/jcm10081660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhao SS, Mackie SL, Zheng J. Why clinicians should know about Mendelian randomization. Rheumatology (Oxford) 2021;60:1577-9. [PMID: 33493347 DOI: 10.1093/rheumatology/keab007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Holdsworth G, Staley JR, Hall P, van Koeverden I, Vangjeli C, Okoye R, Boyce RW, Turk JR, Armstrong M, Wolfreys A, Pasterkamp G. Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans. J Bone Miner Res 2021;36:1326-39. [PMID: 33784435 DOI: 10.1002/jbmr.4287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
19 Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol 2021;18:435-53. [PMID: 33707768 DOI: 10.1038/s41569-020-00493-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
20 Wang JS, Mazur CM, Wein MN. Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones. Front Endocrinol (Lausanne) 2021;12:584147. [PMID: 33776907 DOI: 10.3389/fendo.2021.584147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
21 Anastasilakis AD, Tsourdi E, Tabacco G, Naciu AM, Napoli N, Vescini F, Palermo A. The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News? J Clin Med 2021;10:996. [PMID: 33801212 DOI: 10.3390/jcm10050996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Yavropoulou MP, Makras P. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas 2021;147:19-25. [PMID: 33832643 DOI: 10.1016/j.maturitas.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cosman F, Dempster DW. Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose? Curr Osteoporos Rep 2021;19:189-205. [PMID: 33635520 DOI: 10.1007/s11914-021-00663-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
24 Tobias JH, Duncan EL, Kague E, Hammond CL, Gregson CL, Bassett D, Williams GR, Min JL, Gaunt TR, Karasik D, Ohlsson C, Rivadeneira F, Edwards JR, Hannan FM, Kemp JP, Gilbert SJ, Alonso N, Hassan N, Compston JE, Ralston SH. Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. Front Endocrinol (Lausanne) 2020;11:630875. [PMID: 33658983 DOI: 10.3389/fendo.2020.630875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kocijan R, Haschka J, Feurstein J, Zwerina J. New therapeutic options for bone diseases. Wien Med Wochenschr 2021;171:120-5. [PMID: 33512621 DOI: 10.1007/s10354-020-00810-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Stegen S, Devignes C, Torrekens S, Van Looveren R, Carmeliet P, Carmeliet G. Glutamine Metabolism in Osteoprogenitors Is Required for Bone Mass Accrual and PTH ‐Induced Bone Anabolism in Male Mice. J Bone Miner Res 2021;36:604-16. [DOI: 10.1002/jbmr.4219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
27 Bao J, Yang Y, Xia M, Sun W, Chen L. Wnt signaling: An attractive target for periodontitis treatment. Biomed Pharmacother 2021;133:110935. [PMID: 33227711 DOI: 10.1016/j.biopha.2020.110935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
28 Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C, Carrillo-López N. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int 2021;108:410-22. [PMID: 33190187 DOI: 10.1007/s00223-020-00777-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lima JG, Nóbrega LHC, Santos MCF, Simas BCC. Bone mineral density as a surrogate biomarker for fracture risk reduction. The Lancet Diabetes & Endocrinology 2020;8:875-6. [DOI: 10.1016/s2213-8587(20)30339-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Fabre S, Funck-Brentano T, Cohen-Solal M. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. J Clin Med 2020;9:E3439. [PMID: 33114755 DOI: 10.3390/jcm9113439] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]